KMID : 0882420140870040496
|
|
Korean Journal of Medicine 2014 Volume.87 No. 4 p.496 ~ p.500
|
|
Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome
|
|
Kim Ho-Cheol
Kim Sang-Hyung Ahn Ji-Hwan Kwon Hye-Mi Choi Jong-Han Kim Tae-Hyung Lee Je-Hwan
|
|
Abstract
|
|
|
In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients with higher-risk disease. A 78- year-old male was administered the first cycle of azacitidine treatment for higher-risk MDS. On day three of chemotherapy he complained of fever and dyspnea, and radiographic findings revealed bilateral perihilar-peribronchial infiltration and a small amount of pleural effusion. Considering the possibility of pneumonia, intravenous broad-spectrum antibiotics were administered and azacitidine therapy was discontinued. Upon improvement of the patient¡¯s subjective symptoms and radiographic abnormalities, azacitidine therapy was resumed. However, fever and dyspnea developed again upon recommencement of azacitidine therapy. A diagnosis was made of azacitidine-induced lung injury and corticosteroid treatment was administered. Although lung injury is a rare complication induced by azacitidine, physicians should be aware of this life-threatening side effect.
|
|
KEYWORD
|
|
Myelodysplastic Syndrome, Azacitidine, Lung injury
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|